Opus Genetics Inc (IRD)

$2.32 +0.01 (0.43%)
Market Cap 159.31M
Revenue (ttm) 10.99M
Net Income (ttm) -57.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -523.48%
Debt to Equity Ratio 0.18
Volume 493,900
Avg Vol 569,838
Day's Range N/A - N/A
Shares Out 68.96M
Stochastic %K 12%
Beta 0.41
Analysts Strong Sell
Price Target $7.73

Company Profile

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal do...

Industry: Biotechnology
Sector: Healthcare
Phone: 984 884 6030
Website: opusgtx.com
Address:
8 Davis Drive, Suite 220, Durham, United States
signaljumper
signaljumper Feb. 3 at 3:45 PM
$IRD Yesterday i collect more shares for my Portfolio. Today Looks Like we turnaround. In the coming weeks we will see again new highs. Follow me at paetron
0 · Reply
JoeD32
JoeD32 Jan. 30 at 3:02 PM
$IRD got back on the ride from 2.20-2.88 and got off….you’ll be able to buy this under $2 next week
0 · Reply
TickrTalk0007
TickrTalk0007 Jan. 29 at 1:51 PM
$IRD keep an eye on the ATM...notorious for running the ATM
0 · Reply
Sciguy67
Sciguy67 Jan. 28 at 4:17 PM
$IRD had. 1 million buy block earlier today. Someone is accumulating
0 · Reply
Big_Zack22
Big_Zack22 Jan. 28 at 3:03 PM
$IRD break 3 today
0 · Reply
Atime2Buy
Atime2Buy Jan. 28 at 2:38 PM
$IRD Good Money….. i mean Good Morning money makers!
0 · Reply
Big_Zack22
Big_Zack22 Jan. 27 at 6:29 PM
$IRD We might close green. Knowing this ticker
1 · Reply
Um8a123
Um8a123 Jan. 27 at 2:33 PM
$IRD Creating new highs slowly, be patient, this will hit 7 in the next few weeks.
1 · Reply
Novice1a
Novice1a Jan. 27 at 1:51 PM
$IRD did they just dilute the shares by 2 million? how is the new trial they just announced being paid for?
1 · Reply
cuteatheart7
cuteatheart7 Jan. 26 at 10:21 PM
$IRD i am so happy to see this one move 😊
1 · Reply
Latest News on IRD
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

Feb 2, 2026, 8:00 AM EST - 1 day ago

Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

Jan 27, 2026, 7:00 AM EST - 7 days ago

Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

Opus Genetics, Inc. (IRD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 15, 2026, 3:26 PM EST - 18 days ago

Opus Genetics, Inc. (IRD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

Jan 8, 2026, 7:00 AM EST - 26 days ago

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 16, 2025, 4:01 PM EST - 6 weeks ago

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference

Dec 11, 2025, 7:00 AM EST - 7 weeks ago

Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Dec 9, 2025, 7:00 AM EST - 2 months ago

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Opus Genetics to Participate in Upcoming Investment Conferences

Nov 20, 2025, 8:00 AM EST - 2 months ago

Opus Genetics to Participate in Upcoming Investment Conferences

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Nov 13, 2025, 7:00 AM EST - 2 months ago

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

Nov 12, 2025, 7:00 AM EST - 2 months ago

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

Opus Genetics Announces $23 Million Registered Direct Offering

Nov 6, 2025, 7:00 AM EST - 3 months ago

Opus Genetics Announces $23 Million Registered Direct Offering

Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Nov 6, 2025, 7:00 AM EST - 3 months ago

Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Oct 14, 2025, 8:00 AM EDT - 4 months ago

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

Oct 2, 2025, 8:00 AM EDT - 4 months ago

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

Opus Genetics, Inc. - Special Call

Sep 30, 2025, 12:12 PM EDT - 4 months ago

Opus Genetics, Inc. - Special Call

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

Sep 30, 2025, 7:00 AM EDT - 4 months ago

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Sep 4, 2025, 8:00 AM EDT - 5 months ago

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 5 months ago

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Sep 2, 2025, 8:00 AM EDT - 5 months ago

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Aug 27, 2025, 8:00 AM EDT - 5 months ago

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Aug 18, 2025, 8:00 AM EDT - 6 months ago

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Aug 13, 2025, 4:30 PM EDT - 6 months ago

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 5, 2025, 8:00 AM EDT - 6 months ago

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Jul 23, 2025, 8:00 AM EDT - 6 months ago

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 3, 2025, 4:30 PM EDT - 7 months ago

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Jun 26, 2025, 6:55 AM EDT - 7 months ago

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

Jun 23, 2025, 8:00 AM EDT - 8 months ago

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Jun 2, 2025, 8:00 AM EDT - 8 months ago

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

May 15, 2025, 8:00 AM EDT - 9 months ago

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

May 12, 2025, 8:00 AM EDT - 9 months ago

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

May 6, 2025, 8:00 AM EDT - 9 months ago

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

May 5, 2025, 8:00 AM EDT - 9 months ago

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Apr 11, 2025, 3:47 PM EDT - 10 months ago

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Apr 8, 2025, 8:00 AM EDT - 10 months ago

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Opus Genetics to Participate in Upcoming Investor Conference in April

Apr 2, 2025, 8:00 AM EDT - 10 months ago

Opus Genetics to Participate in Upcoming Investor Conference in April

Opus Genetics Announces Financial Results for Full Year 2024

Mar 31, 2025, 8:20 AM EDT - 11 months ago

Opus Genetics Announces Financial Results for Full Year 2024

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Mar 21, 2025, 5:03 PM EDT - 11 months ago

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Mar 21, 2025, 9:30 AM EDT - 11 months ago

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Mar 21, 2025, 9:11 AM EDT - 11 months ago

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Mar 5, 2025, 8:00 AM EST - 11 months ago

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Feb 26, 2025, 8:00 AM EST - 1 year ago

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Feb 18, 2025, 7:30 AM EST - 1 year ago

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

Feb 7, 2025, 9:15 AM EST - 1 year ago

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

XBI

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Dec 19, 2024, 8:00 AM EST - 1 year ago

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

signaljumper
signaljumper Feb. 3 at 3:45 PM
$IRD Yesterday i collect more shares for my Portfolio. Today Looks Like we turnaround. In the coming weeks we will see again new highs. Follow me at paetron
0 · Reply
JoeD32
JoeD32 Jan. 30 at 3:02 PM
$IRD got back on the ride from 2.20-2.88 and got off….you’ll be able to buy this under $2 next week
0 · Reply
TickrTalk0007
TickrTalk0007 Jan. 29 at 1:51 PM
$IRD keep an eye on the ATM...notorious for running the ATM
0 · Reply
Sciguy67
Sciguy67 Jan. 28 at 4:17 PM
$IRD had. 1 million buy block earlier today. Someone is accumulating
0 · Reply
Big_Zack22
Big_Zack22 Jan. 28 at 3:03 PM
$IRD break 3 today
0 · Reply
Atime2Buy
Atime2Buy Jan. 28 at 2:38 PM
$IRD Good Money….. i mean Good Morning money makers!
0 · Reply
Big_Zack22
Big_Zack22 Jan. 27 at 6:29 PM
$IRD We might close green. Knowing this ticker
1 · Reply
Um8a123
Um8a123 Jan. 27 at 2:33 PM
$IRD Creating new highs slowly, be patient, this will hit 7 in the next few weeks.
1 · Reply
Novice1a
Novice1a Jan. 27 at 1:51 PM
$IRD did they just dilute the shares by 2 million? how is the new trial they just announced being paid for?
1 · Reply
cuteatheart7
cuteatheart7 Jan. 26 at 10:21 PM
$IRD i am so happy to see this one move 😊
1 · Reply
Atime2Buy
Atime2Buy Jan. 26 at 9:04 PM
$IRD great day today
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 26 at 8:27 PM
$IRD Current Stock Price: $2.80 Contracts to trade: $2.5 IRD Feb 20 2026 Call Entry: $0.50 Exit: $0.96 ROI: 91% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
signaljumper
signaljumper Jan. 26 at 7:01 PM
$IRD more Infos and Targets 👇👇
0 · Reply
Atime2Buy
Atime2Buy Jan. 26 at 6:58 PM
$IRD
0 · Reply
Big_Zack22
Big_Zack22 Jan. 26 at 5:55 PM
$IRD Good Job
0 · Reply
signaljumper
signaljumper Jan. 26 at 5:44 PM
$IRD in the next days WE will break 3 bucks. Trade my last postings on this Board. There is a Stock Report with Chart technical and more...
0 · Reply
Um8a123
Um8a123 Jan. 26 at 3:54 PM
$IRD Just accumulate, the graph speaks for itself. We are lucky to be here at these levels. We should hit 7.
0 · Reply
Big_Zack22
Big_Zack22 Jan. 26 at 3:23 PM
$IRD I like the way we are climbing. Out of noise and pumper
0 · Reply
Atime2Buy
Atime2Buy Jan. 26 at 3:10 PM
$IRD its really great to see not only people taking notice but the steady move upward. I’m truly getting excited again. the wait is start to pay off.
0 · Reply
peepthestamp
peepthestamp Jan. 23 at 11:49 PM
$IRD
0 · Reply
TruthTooPower
TruthTooPower Jan. 23 at 2:11 PM
$LASE!!! $INDP !!! $AUUD !!! $IRD !!! Get In On “THE LIST” Baby!!!
0 · Reply
signaljumper
signaljumper Jan. 22 at 5:14 PM
$IRD Opus Genetics Inc (IRD) Under the Microscope: Today’s Stock Action. charting, Infos and more https://www.patreon.com/posts/opus-genetics-01-148862586?utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=postshare_creator&utm_content=join_link
0 · Reply